{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:28:31Z","timestamp":1761611311175,"version":"3.40.3"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T00:00:00Z","timestamp":1349654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Cilostazol (CLZ) and atorvastatin (ATV) are often co\u2010prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug\u2013drug interaction potential of multi\u2010dose ATV co\u2010administration with CLZ on both pharmacokinetics and the anti\u2010thrombotic property of CLZ is demonstrated. The pharmacokinetic parameters of CLZ (6\u2009mg\/kg, twice daily) were determined in male Wistar rats after 7\u2009days co\u2010administration with ATV (5\u2009mg\/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment.<jats:italic>In vitro<\/jats:italic>metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction. Pharmacodynamic drug\u2013drug interaction was evaluated on anti\u2010thrombotic models including time to occlusion, platelet aggregation and rat tail bleeding time. A validated LC\u2010MS\/MS method was employed simultaneously to quantify both ATV and CLZ in rat plasma matrix. A statistically significant increase in systemic exposure (<jats:italic>C<\/jats:italic>ss<jats:sub>max<\/jats:sub>by ~1.75 fold;<jats:italic>AUC<\/jats:italic>by ~3.0 fold) to CLZ was observed in ATV pre\u2010treated rats.<jats:italic>In vitro<\/jats:italic>metabolism studies using liver microsomes (RLM and HLM) demonstrated statistically significant inhibition of CLZ metabolism when co\u2010incubated with ATV. No change in apparent permeability of CLZ was observed in the presence of ATV. Atorvastatin showed a significant delay in artery occlusion time without altering CLZ's bleeding time and platelet aggregation profile. Collectively the results of these studies provide metabolic insight into the nature of drug\u2013drug interaction between the selected drugs. Co\u2010administration with ATV influences the pharmacokinetics and anti\u2010thrombotic property of CLZ. A thorough clinical investigation is required before extrapolation of data to humans. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.1812","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T16:26:24Z","timestamp":1346343984000},"page":"455-465","source":"Crossref","is-referenced-by-count":6,"title":["Drug\u2013drug interaction study to assess the effects of atorvastatin co\u2010administration on pharmacokinetics and anti\u2010thrombotic properties of cilostazol in male Wistar rats"],"prefix":"10.1002","volume":"33","author":[{"given":"Rahul","family":"Vats","sequence":"first","affiliation":[{"name":"BITS\u2010Pilani Hyderabad Campus, Pharmacy Department Hyderabad Campus Hyderabad Andhra Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanthikiran V. S.","family":"Varanasi","sequence":"additional","affiliation":[{"name":"Glenmark Research Centre, Glenmark Pharmaceuticals Ltd, Drug Metabolism and Pharmacokinetics Mumbai Maharastra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rambabu","family":"Arla","sequence":"additional","affiliation":[{"name":"Glenmark Research Centre, Glenmark Pharmaceuticals Ltd, Drug Metabolism and Pharmacokinetics Mumbai Maharastra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Veeraraghvan","sequence":"additional","affiliation":[{"name":"Glenmark Research Centre, Glenmark Pharmaceuticals Ltd, Drug Metabolism and Pharmacokinetics Mumbai Maharastra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Rajak","sequence":"additional","affiliation":[{"name":"Glenmark Research Centre, Glenmark Pharmaceuticals Ltd, Drug Metabolism and Pharmacokinetics Mumbai Maharastra India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1317"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-44"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105243442108"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-17969-3_9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.12.1942"},{"key":"e_1_2_7_8_1","first-page":"1133","article-title":"The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man","volume":"35","author":"Akiyama H","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032700678827717"},{"key":"e_1_2_7_10_1","unstructured":"http:\/\/www.rxlist.com\/pletal\u2013drug.htm[18 July 2012]."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937002-00001"},{"key":"e_1_2_7_12_1","first-page":"1124","article-title":"The absorption, distribution and excretion of a new anti thrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man","volume":"35","author":"Akiyama H","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10490"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241050-00003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/107424840200700408"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04015.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.009076"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0090-9556(24)15242-7","article-title":"Metabolism and excretion of atorvastatin between rats and dogs","volume":"27","author":"Black AE","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_20_1","first-page":"153","article-title":"Metabolism and excretion of [14C]\u2010atorvastatin in patients with T\u2010tube drainage","volume":"3","author":"Le Couteur DG","year":"1996","journal-title":"Proc Aust Soc Clin Exp Pharmacol Toxicol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000041466.84653.8c"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004000112"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937002-00007"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2001.23.10.677120"},{"key":"e_1_2_7_25_1","unstructured":"Pletal tablets 100\u2009mg. Patient information leaflet distributed by Otsuka Pharmaceuticals Ltd (UK).http:\/\/www.mhra.gov.uk\/home\/groups\/pla\/documents\/websiteresources \/con020797.pdf[20 July 2012]."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj1280001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00312.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.4593"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042\u20137158.2012.01542.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(90)90106-M"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(95)93881-Y"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.02.013"},{"volume-title":"Guidance for Industry: Bio Analytical Method Validation","year":"2001","author":"Food and Drug Administration (FDA)","key":"e_1_2_7_33_1"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.590242"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937002-00002"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmor.1051470305"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.10.1235"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.1.4.641"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9249-7"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.5.505"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.1.53"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04034.x"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.1812","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.1812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T14:56:18Z","timestamp":1744037778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.1812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/bdd.1812"],"URL":"https:\/\/doi.org\/10.1002\/bdd.1812","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"type":"print","value":"0142-2782"},{"type":"electronic","value":"1099-081X"}],"subject":[],"published":{"date-parts":[[2012,10,8]]}}}